Shan Lv

Dr. Shan Lv


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2014 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
ZCZhuo Chen
Zhuo Chen
QLQin Liu
Qin Liu
JLJi-Qi Liu
Ji-Qi Liu
BXBianli Xu
Bianli Xu
SLShan Lv
Shan Lv
XZXiao-Nong Zhou
Xiao-Nong Zhou
Ticks can transmit a number of pathogens to humans and domestic animals. Tick borne diseases (TBDs), which may lead to organ failure and death have been recently reported in China. 98.75% of the total cases (>1000) in Henan provinces have been reported in Xinyang city. Therefore, the aims of this study were to investigate the fauna of ticks and detect the potential pathogens in ticks in Xinyang, the region of central China.

2 October 2007 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
LLLan Hua Li
Lan Hua Li
XZXiao Ping Zhang
Xiao Ping Zhang
SLShan Lv
Shan Lv
LZLing Zhang
Ling Zhang
HYHisao Yoshikawa
Hisao Yoshikawa
XZXiao-Nong Zhou
Xiao-Nong Zhou

Verified
Journal Article
Open access
PDF file
NTNa Tian
Na Tian
JZJin-Xin Zheng
Jin-Xin Zheng
ZGZhaoyu Guo
Zhaoyu Guo
LLLan-Hua Li
Lan-Hua Li
SXShang Xia
Shang Xia
XZXiao-Nong Zhou
Xiao-Nong Zhou
Background: Dengue has become one of the major vector-borne diseases, which has been an important public health concern. We aimed to estimate the disease burden of dengue in major endemic regions from 1990 to 2019, and explore the impact pattern of the socioeconomic factors on the burden of dengue based on the global burden of diseases, injuries, and risk factors study 2019 (GBD 2019). Methods: Using the analytical strategies and data from the GBD 2019, we described the incidence and disability-adjusted life years (DALYs) of dengue in major endemic regions from 1990 to 2019. Furthermore, we estimated the correlation between dengue burden and socioeconomic factors, and then established an autoregressive integrated moving average (ARIMA) model to predict the epidemic trends of dengue in endemic regions. All estimates were proposed as numbers and age-standardized rates (ASR) per 100,000 population, with uncertainty intervals (UIs). The ASRs of dengue incidence were compared geographically and five regions were stratified by a sociodemographic index (SDI). Results: A significant rise was observed on a global scale between 1990 and 2019, with the overall age-standardized rate (ASR) increasing from 557.15 (95% UI 243.32–1212.53) per 100,000 in 1990 to 740.4 (95% UI 478.2–1323.1) per 100,000 in 2019. In 2019, the Oceania region had the highest age-standardized incidence rates per 100,000 population (3173.48 (95% UI 762.33–6161.18)), followed by the South Asia region (1740.79 (95% UI 660.93–4287.12)), and then the Southeast Asia region (1153.57 (95% UI 1049.49–1281.59)). In Oceania, South Asia, and Southeast Asia, increase trends were found in the burden of dengue fever measured by ASRs of DALY which were consistent with ASRs of dengue incidence at the national level. Most of the countries with the heaviest burden of dengue fever occurred in areas with low and medium SDI regions. However, the burden in high-middle and high-SDI countries is relatively low, especially the Solomon Islands and Tonga in Oceania, the Maldives in South Asia and Indonesia in Southeast Asia. The age distribution results of the incidence rate and disease burden of dengue fever of major endemic regions showed that the higher risk and disease burden are mainly concentrated in people under 14 or over 70 years old. The prediction by ARIMA showed that the risk of dengue fever in South and Southeast Asia is on the rise, and further prevention and control is warranted. Conclusions: In view of the rapid population growth and urbanization in many dengue-endemic countries, our research results are of great significance for presenting the future trend in dengue fever. It is recommended to policy makers that specific attention needs to be paid to the negative impact of urbanization on dengue incidence and allocate more resources to the low-SDI areas and people under 14 or over 70 years old to reduce the burden of dengue fever.

11 February 2011 in Freshwater Biology
Verified
Journal Article
Closed access
PDF file
SLShan Lv
Shan Lv
YZYi Zhang
Yi Zhang
PSPeter Steinmann
Peter Steinmann
GYGuo‐Jing Yang
Guo‐Jing Yang
KYKun Yang
Kun Yang
JUJürg Utzinger
Jürg Utzinger

27 January 2009 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
SLShan Lv
Shan Lv
YZYi Zhang
Yi Zhang
HLHe-Xiang Liu
He-Xiang Liu
CZChao-Wei Zhang
Chao-Wei Zhang
PSPeter Steinmann
Peter Steinmann
JUJürg Utzinger
Jürg Utzinger

8 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJia-Xu Chen
Jia-Xu Chen
MCMu-Xin Chen
Mu-Xin Chen
LALin Ai
Lin Ai
XXXue-Nian Xu
Xue-Nian Xu
JJJian-Ming Jiao
Jian-Ming Jiao
XZXiao-Nong Zhou
Xiao-Nong Zhou
Fascioliasis is a common parasitic disease in livestock in China. However, human fascioliasis is rarely reported in the country. Here we describe an outbreak of human fascioliasis in Yunnan province. We reviewed the complete clinical records of 29 patients and performed an epidemiological investigation on the general human population and animals in the outbreak locality. Our findings support an outbreak due to Fasciola gigantica with a peak in late November, 2011. The most common symptoms were remittent fever, epigastric tenderness, and hepatalgia. Eosinophilia and tunnel-like lesions in ultrasound imaging in the liver were also commonly seen. Significant improvement of patients’ condition was achieved by administration of triclabendazole®. Fasciola spp. were discovered in local cattle (28.6%) and goats (26.0%). Molecular evidence showed a coexistence of F. gigantica and F. hepatica. However, all eggs seen in humans were confirmed to be F. gigantica. Herb (Houttuynia cordata) was most likely the source of infections. Our findings indicate that human fascioliasis is a neglected disease in China. The distribution of triclabendazole®, the only efficacious drug against human fascioliasis, should be promoted.